Jazz Pharmaceuticals (NASDAQ:JAZZ) stock drops 6% amid biopharma selloff after a $145M antitrust settlement over Xyrem ...

Share price of JAZZ Pharmaceuticals JAZZ hit $102.82 on Tuesday, close to its 52-week low of $99.06. This decline is ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

Jazz Pharmaceuticals said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem.

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Learn more about whether Jazz Pharmaceuticals plc or Merck & Co., Inc. is a better investment based on AAII's A+ Investor ...

Learn more about whether Jazz Pharmaceuticals plc or Johnson & Johnson is a better investment based on AAII's A+ Investor ...

Sei Investments Co. decreased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 30.5% in the 4th quarter, ...

Avadel has initiated four patent infringement lawsuits against Jazz Pharmaceuticals since the beginning of 2025, alleging certain uses of Jazz’s Xywav product, according to its corresponding labeling, ...

Avadel Pharmaceuticals (AVDL) presented at the 24th Annual Needham Virtual Healthcare Conference, at which the company provided an update on ...

On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ‘Power Lunch’ to discuss investing in biotech and the oversaturation in the sector. He said that looking at ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on ...